Cardiol Therapeutics
CRDL
28 hedge funds and large institutions have $8.27M invested in Cardiol Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 12 closing their positions.
1,688% more call options, than puts
Call options by funds: $1.88M | Put options by funds: $105K
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
0.82% less ownership
Funds ownership: 9.52% → 8.7% (-0.82%)
15% less funds holding
Funds holding: 33 → 28 (-5)
23% less capital invested
Capital invested by funds: $10.7M → $8.27M (-$2.46M)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$567K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$179K |
| 3 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$165K |
| 4 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$121K |
| 5 |
RSWM
Robertson Stephens Wealth Management
San Francisco,
California
|
+$45.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$847K |
| 2 |
Two Sigma Investments
New York
|
-$360K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$245K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$184K |
| 5 |
Renaissance Technologies
New York
|
-$171K |
CRDL Hedge Fund Activity: Q1 2022 in Review
28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q1 2022, worth a combined $8.27M — down 23% from $10.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CRDL and 7 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 9 added.
The largest buyer was Mirae Asset Global Investments, adding an estimated $567K. The largest seller was Verition Fund Management, exiting entirely with an estimated $847K sold.
- 28 institutional investors held Cardiol Therapeutics (CRDL) as of Q1 2022, down from 33 in Q4 2021.
- Funds reported $8.27M of Cardiol Therapeutics stock for Q1 2022, down 23% quarter-over-quarter.
- 7 funds opened new Cardiol Therapeutics positions in Q1 2022 and 12 closed out, a net change of -5 holders.
- The largest Cardiol Therapeutics buyer in Q1 2022 was Mirae Asset Global Investments, an estimated $567K added.
- The largest Cardiol Therapeutics seller in Q1 2022 was Verition Fund Management, an estimated $847K sold.
Based on aggregated 13F filings for Q1 2022.